You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
San Carlos, California
52 Week High
52 Week Low
Expected Aug 6, After Hours